Profusa

Profusa is pioneering a novel class of continuous monitoring biosensors designed to overcome the fundamental biological challenge of foreign body rejection. Its core technology is an injectable hydrogel microsensor, smaller than a grain of rice, which integrates with tissue and functions for up to 9+ months, enabling long-term, calibration-free monitoring of oxygen, glucose, and other analytes. Backed by over $100M in investment, including significant non-dilutive funding from DARPA and the NIH, and protected by 85 global patents, the company is advancing its Lumee™ Oxygen platform toward a CE Mark target in 2026. Profusa's integrated system combines the sensor with a reusable optical reader and an AI-driven data platform, positioning it to address massive markets in diabetes care, wound management, and remote patient monitoring.

Injectable, biocompatible hydrogel microsensor platform for long-term, continuous monitoring of body chemistry (e.g., oxygen, glucose). The system includes a passive sensor, a reusable optical reader, and an AI-driven data analytics platform.

In CGM, Profusa faces entrenched giants like Dexcom and Abbott, competing on longer sensor life and lower cost. In tissue oxygen monitoring, it competes with established oximetry devices. Its key differentiator is the biocompatible hydrogel that avoids foreign body response, enabling unprecedented longevity, which is a significant technological advantage if proven at scale.